Tag John W. Sweetenham

Checkpoint inhibitors revolutionized cancer therapy and the field of oncology when the first drug of this class was introduced for melanoma treatment. But their therapeutic benefit comes at a cost of immunotherapy-related adverse events (IrAEs). Checkpoint inhibitors are immunomodulatory antibodies…